14-day Premium Trial Subscription Sign Up For FreeGet Free

$3.20 (-5.04%)

Volume: 1M

Closed: Nov 29, 2021

Hollow Logo Score: -5.436

Epizyme Stock Forecast

$3.20 (-5.04%)

Volume: 1M

Closed: Nov 29, 2021

Score Hollow Logo -5.436
Which way will EPZM go? Request
Key Stats
Beta 1.2
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 7 and the stock is extremely oversold on RSI14, but some stocks may continue to fall despite the high chance of a correction up. The low RSI lowers the general risk and the stock should be considered if other technical requirements like liquidity and risk-reward are meet.

Epizyme stock price took a fall of -5.04% on Monday
(Updated on Nov 29, 2021)


Sell candidate since 2021-11-29

The Epizyme stock price fell by -5.04% on the last day (Monday, 29th Nov 2021) from $3.37 to $3.20. and has now fallen 3 days in a row. During the day the stock fluctuated 8.78% from a day low at $3.19 to a day high of $3.47. The price has fallen in 8 of the last 10 days and is down by -28.89% for this period. Volume has increased on the last day by 119 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 1 million shares were bought and sold for approximately $3.59 million.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.62) are considered to be a "second chance" to get out. According to the fan-theory $2.66 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Epizyme stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.54 and $4.41. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, November 08, 2021, and so far it has fallen -35.74%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.28 between high and low, or 8.78%. For the last week, the stock has had a daily average volatility of 7.70%.

Epizyme is oversold on RSI14 (7). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Epizyme stock A Buy?

Epizyme holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -5.436

Predicted Opening Price for Epizyme of Tuesday, November 30, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 30, 2021 Current price
$3.29 $3.20 (Undervalued)
Strong Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Aug 10, 2021 "HC Wainwright" gave "$36.00 - $15.00" rating for EPZM. The price target was changed from $5.86 to 9.4%.

Volatility and Risk
Daily Average Volatility: 7.70 %
Overall Risk: Very High High Medium Low Very Low
Volatility
7.70 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $3.48
Price: $3.20
No Support Found

EPZM Insider Trading Show all Trades

INSIDER POWER

19.280

Last 100 transactions
Buy: 3 641 648 | Sell: 188 885 (Shares)
Date Action Amount Person Type
Nov 16, 2021 Buy 83 298 Stuckley Carol Stock Option (Right to Buy)
Nov 16, 2021 Buy 16 702 Stuckley Carol Common Stock, par value $0.0001
Nov 16, 2021 Buy 83 298 Beveridge, Roy A Stock Option (Right to Buy)
Nov 16, 2021 Buy 16 702 Beveridge, Roy A Common Stock, par value $0.0001
Sep 30, 2021 Buy 2 930 Conroy Kevin T Common Stock, par value $0.0001
Show all Insider Trades
INSIDER POWER

19.280

Last 100 transactions
Buy: 3 641 648 | Sell: 188 885 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.57 11.46 %
3.46 8.12 %
3.39 6.05 %
Current price: 3.20
Support 3.18 -0.63 %
3.11 -2.70 %
3.01 -6.04 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.83 19.69 %
3.59 12.19 %
3.48 8.75 %
Current price 3.20
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Epizyme

Epizyme Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company’s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs). Its lead product candidate includes tazemetostat, an inhibitor of the EZH2 HMT, which is in Phase II clinical study in adults with relapsed or refractory non-Hodgkin lymphoma; and in phase II s... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT